![Biomea Fusion, Inc. logo](/logos/BMEA.webp)
Biomea Fusion, Inc.
NASDAQ:BMEA
Overview | Financials
Company Name | Biomea Fusion, Inc. |
Symbol | BMEA |
Currency | USD |
Price | 7.08 |
Market Cap | 256,368,216 |
Dividend Yield | 0% |
52-week-range | 3.61 - 22.74 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Andrew Butler |
Website | https://biomeafusion.com |
An error occurred while fetching data.
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD